संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

taro pharmaceutical industries ltd. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 50 mg in 1 g - fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. in the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. safety and efficacy in other indications have not been established. the diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. with isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. the success rate with fluorouracil cream and solution is approximately 93%, based on 113 lesions in 54 patients. twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. fluorouracil may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies in pregnant women with either the topi

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

fresenius kabi usa, llc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 50 mg in 1 ml - fluorouracil is indicated for the treatment of patients with: • adenocarcinoma of the colon and rectum • adenocarcinoma of the breast • gastric adenocarcinoma • pancreatic adenocarcinoma none. pregnancy category d risk summary there are no adequate and well-controlled studies with fluorouracil in pregnant women. based on its mechanism of action, fluorouracil can cause fetal harm when administered to a pregnant woman. administration of fluorouracil to rats and mice during selected periods of organogenesis, at doses lower than a human dose of 12 mg/kg, caused embryolethality and teratogenicity. malformations included cleft palate and skeletal defects. in monkeys, maternal doses of fluorouracil higher than an approximate human dose of 12 mg/kg resulted in abortion. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus [see clinical pharmacology (12.1)]. animal data malformations including cleft palate, skele

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - fluorouracil sodium - solution for injection/infusion - 25 milligram(s)/millilitre - pyrimidine analogues; fluorouracil

सऊदी अरब - अंग्रेज़ी - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ebewe pharma - fluorouracil - concentrate for solution for injection - 50 mg/ml

सऊदी अरब - अंग्रेज़ी - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ebewe pharma - fluorouracil - concentrate for solution for injection - 50 mg/ml

सऊदी अरब - अंग्रेज़ी - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ebewe pharma, austria - fluorouracil - solution for injection - 50 mg/ml

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

pfizer private limited - fluorouracil - injection - 50 mg/ml - fluorouracil 50 mg/ml

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide - fluorouracil is indicated alone or in combination for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum, and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - fluorouracil is indicated alone or in combination for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.